Stockreport

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEW [Read more]